Senti Bio receives FDA IND clearance for SENTI-202 CAR-NK therapy for AML

Senti Biosciences, Inc.

FDA cleared IND for SENTI-202, an off-the-shelf CAR-NK cell therapy targeting CD33/FLT3 hematologic malignancies including AML.
Phase 1 trial expected to treat first patient in Q2 2024 at multiple US and Australia sites.
Initial efficacy data expected by year-end 2024; durability data expected in 2025.
Trial evaluates two dose levels (1 or 1.5 billion cells) with three weekly doses after lymphodepletion and optional continuation cycles.
Manufacturing expenses for Phase 1 largely prepaid through existing GeneFab agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.